


## PROTAC Bcl2 degrader-1

<b>Cat. No.:</b>	HY-125876
<b>CAS No.:</b>	2378801-85-3
<b>Molecular Formula:</b>	C <sub>45</sub> H <sub>45</sub> BrN <sub>6</sub> O <sub>10</sub> S
<b>Molecular Weight:</b>	941.84
<b>Target:</b>	PROTACs; Bcl-2 Family
<b>Pathway:</b>	PROTAC; Apoptosis
<b>Storage:</b>	-20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 25 mg/mL (26.54 mM; Need ultrasonic)																							
	<table border="1"> <thead> <tr> <th rowspan="2">Preparing Stock Solutions</th> <th rowspan="2">Solvent Concentration</th> <th colspan="3">Mass</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td></td> <td>1 mM</td> <td>1.0618 mL</td> <td>5.3088 mL</td> <td>10.6175 mL</td> </tr> <tr> <td></td> <td>5 mM</td> <td>0.2124 mL</td> <td>1.0618 mL</td> <td>2.1235 mL</td> </tr> <tr> <td></td> <td>10 mM</td> <td>0.1062 mL</td> <td>0.5309 mL</td> <td>1.0618 mL</td> </tr> </tbody> </table>	Preparing Stock Solutions	Solvent Concentration	Mass			1 mg	5 mg	10 mg		1 mM	1.0618 mL	5.3088 mL	10.6175 mL		5 mM	0.2124 mL	1.0618 mL	2.1235 mL		10 mM	0.1062 mL	0.5309 mL	1.0618 mL
Preparing Stock Solutions	Solvent Concentration			Mass																				
		1 mg	5 mg	10 mg																				
	1 mM	1.0618 mL	5.3088 mL	10.6175 mL																				
	5 mM	0.2124 mL	1.0618 mL	2.1235 mL																				
	10 mM	0.1062 mL	0.5309 mL	1.0618 mL																				
	Please refer to the solubility information to select the appropriate solvent.																							
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.65 mM); Clear solution																							

### BIOLOGICAL ACTIVITY

<b>Description</b>	PROTAC Bcl2 degrader-1 (Compound C5) is a PROTAC based on Cereblon ligand, which potently and selectively induces the degradation of Bcl-2 (IC <sub>50</sub> , 4.94 μM; DC <sub>50</sub> , 3.0 μM) and Mcl-1 (IC <sub>50</sub> , 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitor Nap-1 <sup>[1]</sup> .		
<b>IC<sub>50</sub> &amp; Target</b>	Bcl-2 3 μM (DC50)	Bcl-2 4.94 μM (IC <sub>50</sub> )	Mcl-1 11.81 μM (IC <sub>50</sub> )
<b>In Vitro</b>	PROTAC Bcl2 degrader-1 (10 μM, 24 h) time-and concentration-dependent selective depletion of Mcl-1 or Bcl-2 proteins in Hela cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

### REFERENCES

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA